Order Article Reprints

Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, et al. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (¹¹¹In)/Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin^®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers. 2021; 13(11):2828. https://doi.org/10.3390/cancers13112828

Wahl, Richard L., Eric C. Frey, Heather A. Jacene, Brad S. Kahl, Steven Piantadosi, Jesus A. Bianco, Richard J. Hammes, Miah Jung, Wayne Kasecamp, Bin He, and et al. 2021. "Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (¹¹¹In)/Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin^®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels" Cancers 13, no. 11: 2828. https://doi.org/10.3390/cancers13112828

Wahl, R. L., Frey, E. C., Jacene, H. A., Kahl, B. S., Piantadosi, S., Bianco, J. A., Hammes, R. J., Jung, M., Kasecamp, W., He, B., Sgouros, G., Flinn, I. W., & Swinnen, L. J. (2021). Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (¹¹¹In)/Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin^®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers, 13(11), 2828. https://doi.org/10.3390/cancers13112828